Literature DB >> 11072249

In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates.

V Coulon1, A Ravaud, R Gaston, M Delaunay, J L Pariente, D Verdier, V Scrivante, N Gualde.   

Abstract

Presentation of cell-associated antigen to T cells is a critical event in the initiation of an anti-tumor immune response but it appears to often be deficient or limiting. Here we report an experimental system for stimulation of human T lymphocytes using autologous antigen presenting cells (APCs) and autologous tumor cells. Two types of APCs were prepared from human bone marrow: MC and DC. MC were produced by using GM-CSF and SCF. DC were obtained with the same cytokines plus IL-4. DC and MC were generated in parallel from the same patients and their phenotypes and capacities to prime T lymphocytes were analyzed and compared. MC were CD14+, CD1a-, CD33+ and HLA-DR+. Two populations of DC were defined: immature DC were uniformly CD1a-; mature DC expressed CD1a, CD80, CD86, HLA-DR, CD54 and CD58 but lacked surface CD14. Stimulation of autologous T lymphocytes was studied by measuring their proliferation and cytotoxic function. In more than 80% of our experiments the proliferation of autologous T lymphocytes cocultured with APC pulsed or not with tumor cell lysates was higher than that of T cells cultured alone. DC were more effective than MC in stimulating proliferation of lymphocytes. The capacity of a patient's autologous bone marrow-derived APC to stimulate T cells when exposed to autologous tumor cell lysates suggest that such antigen-exposed APC may be useful in specific anti-tumor immunotherapy protocols. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072249     DOI: 10.1002/1097-0215(20001201)88:5<783::aid-ijc16>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.

Authors:  A Ravaud; M Delaunay; C Chevreau; V Coulon; M Debled; C Bret-Dibat; F Courbon; N Gualde; B Nguyen Bui
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

Review 2.  The future of glioblastoma therapy: synergism of standard of care and immunotherapy.

Authors:  Mira A Patel; Jennifer E Kim; Jacob Ruzevick; Gordon Li; Michael Lim
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.